In this episode, we’re joined by Dr. Piraye Yurttas Beim, founder and CEO of Celmatix, a women’s health biotech company. She discusses the funding the company recently received through the Sprint for Women's Health program.
23andMe and Celmatix are combining forces to understand the genomic underpinnings of infertility.
In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.
New York startup Celmatix just raised $5.5 million for its predictive software that determines a woman's likelihood of infertility based on her genomics.